Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination

Cellular Immunology

Volumn 243, Issue 1, 2006, Pages 30-40

  Kuriyama, Hideyuki ^a   Watanabe, Satoshi ^a   Kjaergaard, Jorgen ^a   Tamai, Hidemasa ^a   Zheng, Rongxiu ^a   Weinberg, Andrew D ^b   Hu, Hong Ming ^b   Cohen, Peter A ^a   Plautz, Gregory E ^a   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

Active immunotherapy; DC tumor electrofusion hybrids; IL 12; OX 40R OX 40L interaction

Indexed keywords

ADJUVANT; CANCER VACCINE; DENDRITIC CELL TUMOR FUSION VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; MONOCLONAL ANTIBODY; OX 40 LIGAND MONOCLONAL ANTIBODY; OX 40 RECEPTOR MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ELECTROFUSION (CELL); FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; LIGATION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SECRETORY CELL; SENSITIZATION; SIGNAL TRANSDUCTION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CELL FUSION; DENDRITIC CELLS; FEMALE; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; OX40 LIGAND; SARCOMA, EXPERIMENTAL; VACCINATION;

ANIMALIA;

EID: 33847068762     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2006.11.002     Document Type: Article

References (54)

1. Pardoll D.M. Cancer vaccines. Nat. Med. 4 (1998) 525-531
2. Ribas A., Butterfield L.H., Glaspy J.A., and Economou J.S. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21 (2003) 2415-2432
3. Steinman R.M., and Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 94 (2001) 459-473
4. Schuler G., Schuler-Thurner B., and Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15 (2003) 138-147
5. Engleman E.G. Dendritic cell-based cancer immunotherapy. Semin. Oncol. 30 (2003) 23-29
6. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest. 21 (2003) 873-886
7. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10 (2004) 909-915
8. Wang J., Saffold S., Cao X., Krauss J., and Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161 (1998) 5516-5524
9. Gong J., Avigan D., Chen D., Wu Z., Koido S., Kashiwaba M., and Kufe D. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. USA 97 (2000) 2715-2718
10. Gong J., Nikrui N., Chen D., Koido S., Wu Z., Tanaka Y., Cannistra S., Avigan D., and Kufe D. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165 (2000) 1705-1711
11. Li J., Holmes L.M., Franek K.J., Burgin K.E., Wagner T.E., and Wei Y. Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol. Immunother. 50 (2001) 456-462
12. Koido S., Tanaka Y., Chen D., Kufe D., and Gong J. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J. Immunol. 168 (2002) 2111-2117
13. Lindner M., and Schirrmacher V. Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylene-glycol versus electro-fusion protocols. Eur. J. Clin. Invest. 32 (2002) 207-217
14. Hayashi T., Tanaka H., Tanaka J., Wang R., Averbook B.J., Cohen P.A., and Shu S. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin. Immunol. 104 (2002) 14-20
15. Melcher A., Todryk S., Bateman A., Chong H., Lemoine N.R., and Vile R.G. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res. 59 (1999) 2802-2805
16. Strome S.E., Voss S., Wilcox R., Wakefield T.L., Tamada K., Flies D., Chapoval A., Lu J., Kasperbauer J.L., Padley D., Vile R., Gastineau D., Wettstein P., and Chen L. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 62 (2002) 1884-1889
17. Tanaka Y., Koido S., Ohana M., Liu C., and Gong J. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. J. Immunol. 174 (2005) 1274-1280
18. Avigan D., Gong J., Uhl L., Wu Z., Vasir D., Smith T., Borges V., Atkins M., Stone C., Giallombardo N., Schadt K., Tetreault J.C., and Kufe D. Dendritic cell tumor fusions as a novel tumor vaccine: a phase I trial for patients with metastatic breast cancer. Blood 98 (2001) 14a abstr
19. Kikuchi T., Akasaki Y., Irie M., Homma S., Abe T., and Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 50 (2001) 337-344
20. Marten A., Renoth S., Heinicke T., von Lilienfeld-Toal M., and Schmidt-Wolf I.G.H. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a first clinical phase I/II trial in patients with metastatic renal cell carcinoma. Blood 98 (2001) 40a abstr
21. Avigan D., Vasir B., Gong J., Borges V., Wu Z., Uhl L., Atkins M., Mier J., McDermott D., Smith T., Giallambardo N., Stone C., Schadt K., Dolgoff J., Tetreault J.-C., Villarroel M., and Kufe D. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10 (2004) 4699-4708
22. Neil G.A., and Zimmermann U. Electrofusion. Methods Enzymol. 220 (1993) 174-196
23. White K.L. Electrofusion of mammalian cells. In: Nickoloff J.A. (Ed). Methods in Molecular Biology (1995), The Humana Press, New Jersey 283-293
24. Kuriyama H., Shimizu K., Lee W., Kjaergaard J., Parkhurst M.R., Cohen P.A., and Shu S. Therapeutic vaccine generated by electrofusion of dendritic cells and tumor cells. Dev. Biol. 116 (2003) 169-178
25. Tanaka H., Shimizu K., Hayashi T., and Shu S. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell. Immunol. 220 (2002) 1-12
26. Parkhurst M.R., DePan C., Riley J.P., Rosenberg S.A., and Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J. Immunol. 170 (2003) 5317-5325
27. Kjaergaard J., Shimizu K., and Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell. Immunol. 225 (2003) 65-74
28. Curtsinger J.M., Lins D.C., and Mescher M.F. Signal 3 determines tolerance versus full activation of naïve CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 197 (2003) 1141-1151
29. Watford W.T., Moriguchi M., Morinobu A., and O'Shea J.J. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 14 (2003) 361-368
30. Chen A.I., McAdam A.J., Buhlmann J.E., Scott S., Lupher Jr. M.L., Greenfield E.A., Baum P.R., Fanslow W.C., Calderhead D.M., Freeman G.J., and Sharpe A.H. OX40-ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity 11 (1999) 689-698
31. Taraban V.Y., Rowley T.F., O'Brien L., Chan H.T., Haswell L.E., Green M.H., Tutt A.L., Glennie M.J., and Al-Shamkhani A. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur. J. Immunol. 32 (2002) 3617-3627
32. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23 (2005) 23-68
33. Shimizu K., Kuriyama H., Kjaergaard J., Lee W., Tanaka H., and Shu S. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J. Immunother. 27 (2004) 265-272
34. + T cells. J. Immunol. 169 (2002) 4897-4904
35. Murata K., Ishii N., Takano H., Miura S., Ndhlovu L.C., Nose M., Noda T., and Sugamura K. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J. Exp. Med. 191 (2000) 365-371
36. Yoshizawa H., Sakai K., Chang A.E., and Shu S. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell. Immunol. 134 (1991) 473-479
37. Yoshizawa H., Chang A.E., and Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147 (1991) 729-737
38. Kjaergaard J., Peng L., Cohen P.A., Drazba J.A., and Weinberg A.D. Augmentation vs. Inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J. Immunol. 167 (2001) 6669-6677
39. Cohen P.A., Peng L., Kjaergaard J., Plautz G.E., Finke J.H., Koski G.K., Czerniecki B.J., and Shu S. T cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit. Rev. Immunol. 21 (2001) 157-178
40. Mackey M.F., Gunn J.R., Maliszewsky C., Kijutani H., Noelle R.J., and Barth Jr. R.J. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol. 161 (1998)
41. Zitvogel L., Mayordomo J.I., Tjandrawan T., DeLeo A.B., Clarke M.R., Lotze M.T., and Storkus W.J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183 (1996) 87-97
42. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nat. Rev. Immunol. 3 (2003) 609-620
43. Stacker S.A., and Springer T.A. Leukocyte integrin P150,95 (CD11c/CD18) functions as an adhesion molecule binding to a counter receptor on stimulated epithelium. J. Immunol. 146 (1991) 648-655
44. Kjaergaard J., Wang L.-X., Kuriyama H., Shu S., and Plautz G. Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J. Neurosurg. 103 (2005) 156-164
45. Schmidt C.S., and Mescher M.F. Peptide antigen priming of naïve, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J. Immunol. 168 (2002) 5521-5529
46. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3 (2003) 133-146
47. Valenzuela J.O., Hammerbeck C.D., and Mescher M.F. Cutting Edge: Bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T cells. J. Immunol. 174 (2005) 600-604
48. Grewal I.S., Jianchao X., and Flavell R.A. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 378 (1995) 617-620
49. Stuber E., and Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J. Exp. Med. 183 (1996) 979-989
50. Gramaglia I., Weinberg A.D., Lemon M., and Croft M. OX-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161 (1998) 6510-6517
51. Pan P.Y., Zang Y., Weber K., Meseck M.L., and Chen S.H. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol. Ther. 6 (2002) 528-536
52. Mendel I., and Shevach E.M. Activated T cells express the OX40 ligand: requirements for induction and costimulatory function. Immunology 117 (2005) 196-204
53. Langrish C.L., McKenzie B.S., Wilson N.J., de Waal M.R., Kastelein R.A., and Cua D.J. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202 (2004) 96-105
54. Malmstrom V., Shipton D., Singh B., Al-Shamkhani A., Puklavec M.J., Barclay A.N., and Powrie F. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J. Immunol. 166 (2001) 6972-6981